• Fourth quarter (Q4) 2015 Net Revenues of $3,841,862 increased by 26% versus Q4 2014
• Full year 2015 Net Revenues of $15,388,196 increased by 26% versus 2014
• Q4 2015 Pharmaceutical Net Revenues of $3,779,349 increased by 26% versus Q4 2014
• Full year 2015 Pharmaceutical Net Revenues of $14,412,874 increased by 27% versus 2014
• In Q4 2015, the Company reported non-recurring, non-operating expenses of $292,000 related to the voluntary recall of Aguettant System® Atropine syringes
• Q4 2015 EBITDA¹ of $1,008,662 decreased by 5% versus Q4 2014; without the impact of non-recurring, non-operating recall expenses, Q4 2015 EBITDA¹ would have been $1,300,662 or a 23% increase over Q4 2014
• Full year 2015 EBITDA¹ of $5,118,792 increased by 19% versus 2014; without the impact of non-recurring, non-operating recall expenses, full year 2015 EBITDA¹ would have been $5,410,792 or a 26% increase over 2014
• Q4 2015 Net Income After Tax of $762,602 increased by 1% versus Q4 2014; without the impact of non-recurring, non-operating recall expenses, reported Q4 2015 Net Income After Tax would have been $977,222 or a 30% increase over 2014
• Full year 2015 Net Income After Tax of $3,764,889 increased by 19% over 2014; without the impact of non-recurring, non-operating recall expenses, full year 2015 Net Income After Tax would have been $3,979,509 or a 26% increase over 2014
• Q4 2015 Fully Diluted EPS was $0.05 as compared to $0.05 in Q4 2014; full year 2015 Fully Diluted EPS of $0.26 grew by 18% over 2014 ($0.22); Q4 and full year 2015 Fully Diluted EPS would have been $0.07 and $0.28, respectively, without the impact of non-recurring, non-operating recall expenses
• The Company remains debt-free and has an unutilized operating line of credit with Royal Bank of Canada
• As at December 31, 2015, the Company had cash, cash equivalents and short term investments totalling $9,715,476, an increase of $1,726,336 over 2014
• Working capital, which is the difference between current assets and current liabilities, increased by 39% from $7,786,460 as at December 31, 2014 to $10,821,785 as at December 31, 2015
• Total Shareholders' Equity increased by 49% from $8,160,092 at December 31, 2014 to $12,151,482 at December 31, 2015
• Return on Equity for fiscal 2015 was 37%

"2015 was a year of continued growth for our business both domestically and in international markets" commented René Goehrum, President and CEO of BioSyent. "It marked the sixth consecutive year of strong revenue, profit and EPS growth. We are proud to have doubled our fully diluted EPS in just two years from $0.13 in 2013 to $0.26 in 2015. This strong sales performance and continued profitability growth has allowed us to re-invest in our business to enhance our product portfolio and competitiveness while simultaneously investing in our people for greater functional capability and capacity. The Company made significant investments in new products in 2015, including Cysview®, an innovative technology that aids in the diagnosis and management of non-muscle-invasive bladder cancer, which we started to promote in Q4 last year. We expect to commence shipment of Cysview® in Q2 2016. Overall, we are well-positioned for continued profitable growth."

The CEO presentation on the Q4 2015 Results is available at the following link: www.biosyent.com/q4-15/

The Company's Audited Consolidated Financial Statements and Management's Discussion & Analysis for the years ended December 31, 2015 and 2014 will be posted on www.sedar.com on March 4, 2016.

For a direct market quote (15 minutes delay) for the TSX Venture Exchange and other Company financial information please visit www.tmxmoney.com.

About BioSyent Inc.

Listed on the TSX Venture Exchange under the trading symbol "RX", BioSyent is a profitable growth-oriented specialty pharmaceutical company focused on in-licensing or acquiring innovative pharmaceutical products that have been successfully developed, are safe and effective, and have a proven track record of improving the lives of patients. BioSyent supports the healthcare professionals that treat these patients by marketing its products through its community, hospital and international business units.

As of the date of this press release, the Company has 14,021,195 shares issued and outstanding.

1. EBITDA - is a Non-IFRS Financial Measure. The term EBITDA does not have any standardized meaning under International Financial Reporting Standards ("IFRS") and therefore may not be comparable to similar measures presented by other companies. The Company defines EBITDA as earnings before interest income or expense, income taxes, depreciation and amortization.

This press release may contain information or statements that are forward-looking. The contents herein represent our judgment, as at the release date, and are subject to risks and uncertainties that may cause actual results or outcomes to be materially different from the forward-looking information or statements. Potential risks may include, but are not limited to, those associated with clinical trials, product development, future revenue, operations, profitability and obtaining regulatory approvals.

The TSX Venture Exchange assumes no responsibility for the accuracy of this release and neither approves nor disapproves of the same.